Lv72 热心小伙伴
5001 积分 2021-08-06 加入
呱
MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms
22小时前
已完结
Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice
22小时前
已完结
Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies
6天前
已完结
Treatment of Elderly Patients With Mantle Cell Lymphoma
7天前
已完结
BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies
24天前
已完结
Triplet Therapies in Chronic Lymphocytic Leukemia
1个月前
已完结
Current Treatment of Double Refractory Chronic Lymphocytic Leukemia: A Focus on Novel Drugs
1个月前
已完结
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia
1个月前
已关闭
Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial
1个月前
已完结
Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China
1个月前
已完结
皖公网安备34019202002308
